RxDoctor Payments Data

Heather Gross

Family · Columbus, INNPI 1851066898

Payments from drug & device makers

$6,341in general payments, 2019–2025

Across 150 payments — averaging $42.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Abbott$491
  • Novartis$424
  • Pfizer$254
  • Boehringer Ingelheim$252
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$208
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$2,41438%
  • Food & beverage$3,92762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,341 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$40,651
Medicare patients
212
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$161,708
EntrestoSacubitril/Valsartan99$135,257
JardianceEmpagliflozin103$126,296
XareltoRivaroxaban40$48,408
BrilintaTicagrelor53$38,941
FarxigaDapagliflozin Propanediol20$14,761
Repatha SureclickEvolocumab14$12,077
Metoprolol Succinate379$4,638
Torsemide77$2,179
Rosuvastatin Calcium116$1,177
Diltiazem 24hr Er (Cd)Diltiazem Hcl45$994
Atorvastatin Calcium126$856
Losartan Potassium128$827
ClopidogrelClopidogrel Bisulfate102$826
Furosemide168$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$254$161,708128 claims
NovartisEntresto$424$135,25799 claims
Boehringer IngelheimJardiance$252$126,296103 claims
AstraZenecaBrilinta, Farxiga$187$53,70373 claims
Johnson & JohnsonXarelto$87$48,40840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Columbus

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →